ImmunityBio, Inc. IBRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $88.33M-38.4% | $143.43M-46.0% | $265.45M+154% | $104.64M-42.2% | ||
| $154.48M+2,321% | $6.38M+532% | $1.01M-60.3% | $2.54M-98.1% | ||
| $113.74M+1,403% | $7.57M— | —— | $0— | ||
| $35.3M+836% | $3.77M— | —— | $0— | ||
| $314.88M+70.6% | $184.59M-37.2% | $294.08M+109% | $140.58M-58.0% | ||
| $114.26M-16.7% | $137.09M-6.2% | $146.08M+1.7% | $143.66M+73.4% | ||
| $910K0.0% | $910K-94.7% | $17.09M— | —— | ||
| $12.99M— | —— | $17.09M-14.5% | $20M+1,309% | ||
| $501.9M+31.1% | $382.93M-24.1% | $504.45M+39.2% | $362.36M-22.7% | ||
| $52K— | $0-100% | $64K-16.9% | $77K— | ||
| $61.75M+12.4% | $54.94M-5.7% | $58.28M-88.4% | $500.86M+35.7% | ||
| $324.62M+14.1% | $284.4M+83.0% | $155.42M— | $0— | ||
| $1B+15.0% | $871.06M-20.1% | $1.09B+34.3% | $812.18M+13.9% | ||
| 1.7B+1,941,076% | 85K+26.9% | 67K+59.5% | 42K+5.0% | ||
| -$3.73B-10.4% | -$3.38B-14.0% | -$2.96B-24.5% | -$2.38B-21.2% | ||
| -$500.47M-2.3% | -$489.1M+16.7% | -$586.99M-31.2% | -$447.33M-84.7% | ||
| $501.9M+31.1% | $382.93M-24.1% | $504.45M+39.2% | $362.36M-22.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ImmunityBio, Inc.'s total assets?
- ImmunityBio, Inc. (IBRX) holds $646.6M in total assets, up 112.9% year over year.
- How much debt does ImmunityBio, Inc. have?
- ImmunityBio, Inc. carries $445.4M in total debt against -$870.0M of shareholders' equity, a debt-to-equity ratio of 0.11.
- How much cash does ImmunityBio, Inc. have?
- ImmunityBio, Inc. holds $205.2M in cash and equivalents.
- Can ImmunityBio, Inc. cover its short-term obligations?
- Its current ratio is 6.67 — current assets exceed current liabilities.
- Where does ImmunityBio, Inc.'s balance sheet data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
